SEC Form 4 · accession 0001179110-17-014859

Allergan plc · AGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Commercial Officer

Period of report

Dec 1, 2017

Accepted (ET)

Dec 4, 2017 · 6:21 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001578845

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares, par value $0.0001^F4	Dec 1, 2017	M	9,272	$78.88	A	66,293	D
Ordinary Shares, par value $0.0001^F4	Dec 1, 2017	M	2,535	$78.88	A	68,828	D
Ordinary Shares, par value $0.0001^F3,F4	Dec 1, 2017	S	9,272	$173.89	D	59,556	D
Ordinary Shares, par value $0.0001^F3,F4	Dec 1, 2017	S	2,535	$173.89	D	57,021	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Options to Purchase Common Stock^F1	$78.88	Dec 1, 2017	M	9,272	D	—	Dec 5, 2017	Ordinary Shares	9,272	0	D
Incentive Stock Option^F2	$78.88	Dec 1, 2017	M	2,535	D	—	Dec 5, 2017	Ordinary Shares	2,535	0	D

F1The option vested in five equal installments on December 6, 2008, 2009, 2010, 2011 and 2012.
F2The option vested in two equal installments on December 6, 2011 and 2012.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.51to $174.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.